Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms
Embotrial-1 is an Italian multicenter prospective randomized clinical trial with open-label treatment and blinded outcome assessment (PROBE) to assess the superiority of MMA embolization compared to conservative treatment. The intervention group is MMA embolization and comparator control group is the conservative management with best medical treatment. Patients are randomized 1:1.
- EligibilityCriteria: Inclusion Criteria:  No neurological deficits (Markwalder score ≤1); Unilateral or bilateral cSDH; Subdural Hematoma width ≤ 20 mm; midline shift ≤ 7mm; Independent functional status with mRS score ≤ 2 prior to symptom onset; Likely compliance of the participant in attending follow-up examination.  Exclusion Criteria:  Radiological evidence of an acute or subacute subdural hematoma, subarachnoid hemorrhage, intracerebral hematoma or epidural hematoma; Contraindications to angiography (end stage chronic renal disease, any sign of anatomical variations that could make MMA embolization unsafe, pregnancy); Life expectancy < 1 year; Patients with any kind of ventricular derivation catheter. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult